We are live on ! Find out more
SCM

Superstring Capital Management Portfolio holdings

AUM $140M
1-Year Est. Return 323.19%
This Fund
S&P 500
This Quarter Est. Return
+16.36%
1 Year Est. Return
+323.19%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$140M
AUM Growth
-$46.8M
Cap. Flow
-$52M
Cap. Flow %
-37.18%
Top 10 Hldgs %
57.92%
Holding
59
New
14
Increased
8
Reduced
12
Closed
24

Top Buys

Rank Stock Value
1
SMMT icon
Summit Therapeutics
SMMT
+$14.4M
2
PCVX icon
Vaxcyte
PCVX
+$6M
3
VIR icon
Vir Biotechnology
VIR
+$5.82M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$5.13M
5
GMAB icon
Genmab
GMAB
+$5.02M

Top Sells

Rank Stock Value
1
CDTX
Cidara Therapeutics
CDTX
+$18.8M
2
TERN
Terns Pharmaceuticals
TERN
+$17.9M
3
DVAX
Dynavax Technologies
DVAX
+$8.08M
4
URGN icon
UroGen Pharma
URGN
+$6.64M
5
COGT icon
Cogent Biosciences
COGT
+$5.21M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
51
Revolution Medicines
RVMD
$39.6B
– –
-54,879
Closed -$4.37M
RZLT icon
52
Rezolute
RZLT
$444M
– –
-513,765
Closed -$1.21M
TERN
53
DELISTED
Terns Pharmaceuticals
TERN
– –
-443,777
Closed -$17.9M
TYRA icon
54
Tyra Biosciences
TYRA
$1.91B
– –
-58,677
Closed -$1.54M
VRDN icon
55
Viridian Therapeutics
VRDN
$1.99B
– –
-43,230
Closed -$1.35M
ZBIO
56
Zenas BioPharma
ZBIO
$1.86B
– –
-83,353
Closed -$3.03M
PVLA
57
Palvella Therapeutics
PVLA
$2.26B
– –
-25,469
Closed -$2.67M
AARD
58
Aardvark Therapeutics
AARD
$128M
– –
-69,496
Closed -$912K
SPRB
59
Spruce Biosciences
SPRB
$120M
– –
-12,137
Closed -$1.06M
1 2
3

Similar funds

GIM
Guild Investment Management Los Angeles, California $140M AUM 28.67% 1-Year Est. Return
SLWM
Stone Loft Wealth Management West Chester, Pennsylvania $140M AUM
NWA
Northwest Wealth Advisors Bellingham, Washington $140M AUM
WCM
WealthTrak Capital Management Virginia Beach, Virginia $140M AUM 17% 1-Year Est. Return
JD6
J Digital 6 Chicago, Illinois $140M AUM
CPC
CFC Planning Company Cicero, Indiana $140M AUM 22.33% 1-Year Est. Return
CFG
Chapman Financial Group Kailua, Hawaii $140M AUM 15.83% 1-Year Est. Return
RC
Rexford Capital Bellaire, Texas $140M AUM 28.19% 1-Year Est. Return

Superstring Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Superstring Capital Management held 59 positions worth $140M, down 25% from $187M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Superstring Capital Management withdrew a net $52M in Q1 2026, closing 24 positions and reducing 12 holdings. Its most notable exit was Cidara Therapeutics, an estimated $18.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Superstring Capital Management opened a new position in Summit Therapeutics worth $16.9M.

  • Superstring Capital Management's largest Q1 2026 buy was Summit Therapeutics: 892,873 shares worth $16.9M.
  • Superstring Capital Management added most to Genmab in Q1 2026, an estimated $5.02M increase.
  • Superstring Capital Management's biggest Q1 2026 reduction was UroGen Pharma, cutting an estimated $6.64M.
  • Superstring Capital Management fully exited Cidara Therapeutics in Q1 2026, selling an estimated $18.8M.
  • Superstring Capital Management's ten largest holdings make up 58% of its $140M portfolio in Q1 2026.
  • Superstring Capital Management opened 14 new positions and closed 24 in Q1 2026.
  • Superstring Capital Management's portfolio value fell 25% quarter-over-quarter to $140M.

Based on Superstring Capital Management's 13F filing for Q1 2026, filed 14 May 2026.